CGH
TAK icon

Crossmark Global Holdings’s Takeda Pharmaceutical TAK Stock Holding History

Crossmark Global Holdings’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Buy
783,835
+6,687
+0.9% +$111K 0.16% 140
2026
Q1 		$14.4M Buy
777,148
+31,972
+4% +$561K 0.21% 112
2025
Q4 		$11.6M Buy
745,176
+17,942
+2% +$257K 0.17% 142
2025
Q3 		$10.6M Buy
727,234
+40
+0% +$594 0.16% 153
2025
Q2 		$11.2M Buy
727,194
+330,361
+83% +$4.88M 0.18% 135
2025
Q1 		$5.9M Buy
396,833
+186,349
+89% +$2.61M 0.1% 217
2024
Q4 		$2.79M Buy
210,484
+155,795
+285% +$2.14M 0.05% 327
2024
Q3 		$778K Buy
54,689
+20,055
+58% +$284K 0.01% 691
2024
Q2 		$448K Buy
34,634
+486
+1% +$6.43K 0.01% 884
2024
Q1 		$474K Sell
34,148
-1,517
-4% -$22.1K 0.01% 893
2023
Q4 		$509K Sell
35,665
-619
-2% -$8.78K 0.01% 839
2023
Q3 		$560K Buy
36,284
+421
+1% +$6.52K 0.01% 769
2023
Q2 		$549K Sell
35,863
-2,935
-8% -$48.1K 0.01% 817
2023
Q1 		$640K Sell
38,798
-3,481
-8% -$55.4K 0.02% 723
2022
Q4 		$659K Buy
42,279
+2,760
+7% +$38.5K 0.02% 687
2022
Q3 		$513K Buy
39,519
+5,229
+15% +$72.7K 0.01% 765
2022
Q2 		$482K Sell
34,290
-430
-1% -$6.14K 0.01% 822
2022
Q1 		$497K Sell
34,720
-740
-2% -$10.9K 0.01% 901
2021
Q4 		$483K Buy
35,460
+170
+0.5% +$2.38K 0.01% 908
2021
Q3 		$578K Buy
35,290
+1,860
+6% +$31.2K 0.01% 850
2021
Q2 		$563K Buy
33,430
+130
+0.4% +$2.21K 0.01% 855
2021
Q1 		$608K Sell
33,300
-10,250
-24% -$184K 0.02% 801
2020
Q4 		$793K Buy
43,550
+3,560
+9% +$62.5K 0.02% 640
2020
Q3 		$713K Sell
39,990
-1,160
-3% -$21.1K 0.02% 639
2020
Q2 		$738K Buy
+41,150
New +$739K 0.02% 629

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Crossmark Global Holdings's TAK Position: Q2 2026 in Review

Crossmark Global Holdings increased its Takeda Pharmaceutical (TAK) stake by 0.86% in Q2 2026, buying an estimated $111K and bringing the position to 783,835 shares worth $12.6M. The position accounts for 0.16% of the portfolio, ranked #140.

Crossmark Global Holdings first reported a position in TAK in Q2 2020 and has held it in 25 quarters since. The position peaked at $14.4M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Crossmark Global Holdings held 783,835 shares of Takeda Pharmaceutical worth $12.6M as of Q2 2026.
  • Crossmark Global Holdings bought 6,687 Takeda Pharmaceutical shares in Q2 2026, an estimated $111K.
  • Takeda Pharmaceutical made up 0.16% of Crossmark Global Holdings's portfolio in Q2 2026, its #140 holding.
  • Crossmark Global Holdings first reported a position in Takeda Pharmaceutical in Q2 2020 and has held it in 25 quarters since.
  • Crossmark Global Holdings's Takeda Pharmaceutical position peaked at $14.4M in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.